Black Diamond Therapeutics Inc (nasdaq:BDTX) Share Price

Company Profile

Business description
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
Contact
245 First Street
18th Floor
CambridgeMA02142
USA
T: +1 617 252-0848
https://www.blackdiamondtherapeutics.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
21

Recommended

An Australian fuel shortage is becoming increasingly unlikely, a relief for ASX toll road operator.

Adrian Atkins | 01 June 2026

Priced for perfection.

Simonelle Mody | 31 May 2026

Aussie stock exchange remains materially undervalued despite growing cost concerns.

Roy Van Keulen | 29 May 2026

Index	Last price	Change	% Change
All Ordinaries	8,969.80	23.20	0.26%
CAC 40	8,146.59	36.75	-0.45%
DAX 40	25,003.04	101.66	-0.40%
Dow JONES (US)	51,070.50	38.04	0.07%
FTSE 100	10,338.95	70.33	-0.68%
HKSE	25,398.18	215.79	0.86%
NASDAQ	27,155.17	182.55	0.68%
Nikkei 225	66,934.33	604.83	0.91%
NZX 50 Index	13,244.55	38.44	0.29%
S&P 500	7,612.45	32.39	0.43%
S&P/ASX 200	8,729.40	19.40	0.22%
SSE Composite Index	4,057.74	10.83	-0.27%